Abstract:Introduction: Upregulated telomerase activity is an established hallmark in about 85-90% of cancer malignancies making it an attractive therapeutic target. However, the development of approved small-molecule telomerase inhibitors has been impeded by a lack of structural ambiguity for decades. In our study, we have employed a molecular dynamics approach to validate the binding site of BIBR1532, an approved telomerase inhibitor in the hTERT thumb domain followed by a structure-based drug designing approach to repurpose FDA-approved drugs and identify novel lead compounds targeting the enzyme. Material and Methods: Due to the unavailability of a co-crystalized structure of BIBR1532 with the catalytic hTERT thumb domain, we employed a Molecular dynamics-based method to identify and validate the exact binding site of the inhibitor. Two pharmacophore models were generated for the putative and newly identified binding pockets which were screened virtually through an anti-cancer library and Drug Bank database. The models were validated on the basis of the fit value of the BIBR1532 and selectivity value indicating the favorable feature set required. The top hits obtained were filtered using drug-likeliness parameters like Lipinski, ADME, and TOPKAT followed by redocking into their binding site. Finally, lead molecules that were able to dock in the new pocket were validated using Molecular Dynamics (MD)simulation studies and their binding free energy was calculated using MM-PBSA calculations followed by their evaluation using in-vitro TRAP assay. Results: Structural investigation, molecular docking studies, and confirmatory molecular dynamics revealed that the exact binding site of BIBR1532 is 8.4 Å away from the reported FVYL pocket strikingly with clinically relevant and characteristic interactions conserved. We have identified five lead compounds and four lead compounds from DrugBank and the anti-cancer library respectively, that were stable in the new binding pocket based on their MD trajectory analysis, and parameters like RMSD, RMSF, H-bonds and Radius of Gyration as well as their MM-PBSA scores. The lead compounds are being evaluated in vitro using TRAP assay and ex-vivo assays. Conclusion: The study identified five existing FDA-approved drugs in the market for other diseases as potential telomerase inhibitors alongside four novel compounds that can be used for the treatment of cancer in the future after further validation studies. Citation Format: Divpreet Kaur, Madhu Chopra, Daman Saluja. Identification of novel lead compounds and repurposing FDA approved drugs as telomerase inhibitors using structure-based drug designing approach and their evaluation using in-vitro and ex-vivo assays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4485.

Synthesis of a thiophene-based fluorinated library applied to fragment-based drug discovery via 19F NMR with confirmed binding to mutant HRASG12V

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Design and Crystallographic Screening of a Highly Sociable and Diverse Fragment Library Towards Novel Antituberculotic Drugs

Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

Design, Synthesis and Biological Evaluation of a Series of Novel 2-Benzamide-4-(6-oxy-n-methyl-1-naphthamide)-pyridine Derivatives As Potent Fibroblast Growth Factor Receptor (FGFR) Inhibitors

LASSBio Chemical Library Diversity and FLT3 New Ligand Identification

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

The Synthesis and Bioactivity of Pyrrolo[2,3-D]pyrimidine Derivatives As Tyrosine Kinase Inhibitors for NSCLC Cells with EGFR Mutations.

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

Rational fragment-based design of compounds targeting the PWWP domain of the HRP family

Synthesis and antiproliferative activity of a tetrahydrofuran analog of FR901464

Abstract 4485: Identification of novel lead compounds and repurposing FDA approved drugs as telomerase inhibitors using structure-based drug designing approach and their evaluation using in-vitro and ex-vivo assays

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Efficient synthesis and cytotoxic activity of polysubstituted thieno[2,3-d]pyrimidine derivatives

Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors

Synthesis, Biological Evaluation and Molecular Docking Studies of 1,3,4-Thiadiazole Derivatives Containing 1,4-Benzodioxan As Potential Antitumor Agents

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors

Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation

Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy